AZELEAD

AZELEAD responds to this need by proposing innovative solutions in the development of new drugs

In recent years, we have observed a high turnover in the development of new drugs, with a failure rate of almost 84% attributed to the low efficacy/toxicity benefit.

Pharmaceutical companies attribute this reduction to the transposability between in vitro and in vivo studies, highlighting the need for new predictive models.

AZELEAD responds to this need by proposing innovative solutions in these main therapeutic areas.

Our models are developed using zebrafish, a completely transparent fish that allows real time visualization of the efficacy of a drug and its side effects on the body.

AZELEAD works on therapeutic fields such as:

  • Oncology
  • Infection
  • Neurological disorders
  • Toxicity
  • Ecotoxicology
  • Rare diseases

 

Laura Fontenille

CEO

www.azelead.com


LPHI  Laboratory of Pathogen Host Interactions
UMR 5235 - Université Montpellier
Place Eugène Bataillon, Bât. 24, CC107, 2ème étage
34095 Montpellier cedex 5

© 2020 LPHI